|
1
|
Gonzalez-Angulo AM, Morales-Vasquez F and
Hortobagyi GN: Overview of resistance to systemic therapy in
patients with breast cancer. Adv Exp Med Biol. 608:1–22. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lozano R, Naghavi M, Foreman K, Lim S,
Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, et
al: Global and regional mortality from 235 causes of death for 20
age groups in 1990 and 2010: A systematic analysis for the Global
Burden of Disease Study 2010. Lancet. 380:2095–2128. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008 GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
National Cancer Institute; Altekruse SF,
Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J,
Howlader N, Tatalovich Z, Cho H, et al: SEER Cancer Statistics
Review, 1975–2007. National Cancer Institute; Bethesda, MD:
http://seer.cancer.gov/csr/1975_2007/
|
|
6
|
Acharyya S, Oskarsson T, Vanharanta S,
Malladi S, Kim J, Morris PG, Manova-Todorova K, Leversha M, Hogg N,
Seshan VE, et al: A CXCL1 paracrine network links cancer
chemoresistance and metastasis. Cell. 150:165–178. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jones SE: Metastatic breast cancer: The
treatment challenge. Clin Breast Cancer. 8:224–233. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Suba Z: Triple-negative breast cancer risk
in women is defined by the defect of estrogen signaling: Preventive
and therapeutic implications. Onco Targets Ther. 7:147–164. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Clark O, Botrel TE, Paladini L and
Ferreira MB: Targeted therapy in triple-negative metastatic breast
cancer: A systematic review and meta-analysis. Core Evid. 9:1–11.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
André F and Zielinski CC: Optimal
strategies for the treatment of metastatic triple-negative breast
cancer with currently approved agents. Ann Oncol. 23 Suppl
6:vi46–vi51. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu Y, Sarkissyan M, Elshimali Y and
Vadgama JV: Triple negative breast tumors in African-American and
Hispanic/Latina women are high in CD44+, low in CD24+, and have
loss of PTEN. PLoS One. 8:e782592013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Elias AD: Triple-negative breast cancer: A
short review. Am J Clin Oncol. 33:637–645. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Miles DW, Chan A, Dirix LY, Cortés J,
Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F,
et al: Phase III study of bevacizumab plus docetaxel compared with
placebo plus docetaxel for the first-line treatment of human
epidermal growth factor receptor 2-negative metastatic breast
cancer. J Clin Oncol. 28:3239–3247. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Miller K, Wang M, Gralow J, Dickler M,
Cobleigh M, Perez EA, Shenkier T, Cella D and Davidson NE:
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic
breast cancer. N Engl J Med. 357:2666–2676. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Feliciano P: CXCL1 and CXCL2 link
metastasis and chemoresistance. Nat Genet. 44:8402012. View Article : Google Scholar
|
|
16
|
Opdenakker G and Van Damme J: The
countercurrent principle in invasion and metastasis of cancer
cells. Recent insights on the roles of chemokines. Int J Dev Biol.
48:519–527. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Van der Cappellen J, Van Damme J and
Struyf S: The role of CXC chemokines and their receptors in cancer.
Cancer Lett. 267:226–244. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dhawan P and Richmond A: Role of CXCL1 in
tumorigenesis of melanoma. J Leukoc Biol. 72:9–18. 2002.PubMed/NCBI
|
|
19
|
Strieter RM, Burdick MD, Mestas J,
Gomperts B, Keane MP and Belperio JA: Cancer CXC chemokine networks
and tumour angiogenesis. Eur J Cancer. 42:768–778. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Richmond A and Thomas HG: Purification of
melanoma growth stimulatory activity. J Cell Physiol. 129:375–384.
1986. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Luan J, Shattuck-Brandt R, Haghnegahdar H,
Owen JD, Strieter R, Burdick M, Nirodi C, Beauchamp D, Johnson KN
and Richmond A: Mechanism and biological significance of
constitutive expression of MGSA/GRO chemokines in malignant
melanoma tumor progression. J Leukoc Biol. 62:588–597.
1997.PubMed/NCBI
|
|
22
|
Wang D and Richmond A: Nuclear
factor-kappa B activation by the CXC chemokine melanoma
growth-stimulatory activity/growth-regulated protein involves the
MEKK1/p38 mitogen-activated protein kinase pathway. J Biol Chem.
276:3650–3659. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wilson C, Purcell C, Seaton A, Oladipo O,
Maxwell PJ, O'Sullivan JM, Wilson RH, Johnston PG and Waugh DJ:
Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling
in metastatic prostate cancer cells confers resistance to
oxaliplatin through potentiation of nuclear factor-kappaB
transcription and evasion of apoptosis. J Pharmacol Exp Ther.
327:746–759. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Richmond A, Lawson DH, Nixon DW and Chawla
RK: Characterization of autostimulatory and transforming growth
factors from human melanoma cells. Cancer Res. 45:6390–6394.
1985.PubMed/NCBI
|
|
25
|
Xia M and Hyman BT: GROalpha/KC, a
chemokine receptor CXCR2 ligand, can be a potent trigger for
neuronal ERK1/2 and PI-3 kinase pathways and for tau
hyperphosphorylation - a role in Alzheimer's disease? J
Neuroimmunol. 122:55–64. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kawanishi H, Matsui Y, Ito M, Watanabe J,
Takahashi T, Nishizawa K, Nishiyama H, Kamoto T, Mikami Y, Tanaka
Y, et al: Secreted CXCL1 is a potential mediator and marker of the
tumor invasion of bladder cancer. Clin Cancer Res. 14:2579–2587.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bandapalli OR, Ehrmann F, Ehemann V, Gaida
M, Macher-Goeppinger S, Wente M, Schirmacher P and Brand K:
Down-regulation of CXCL1 inhibits tumor growth in colorectal liver
metastasis. Cytokine. 57:46–53. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cheng WL, Wang CS, Huang YH, Tsai MM,
Liang Y and Lin KH: Overexpression of CXCL1 and its receptor CXCR2
promote tumor invasion in gastric cancer. Ann Oncol. 22:2267–2276.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Keeley EC, Mehrad B and Strieter RM: CXC
chemokines in cancer angiogenesis and metastases. Adv Cancer Res.
106:91–111. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hartman ZC, Poage GM, den Hollander P,
Tsimelzon A, Hill J, Panupinthu N, Zhang Y, Mazumdar A, Hilsenbeck
SG, Mills GB, et al: Growth of triple-negative breast cancer cells
relies upon coordinate autocrine expression of the proinflammatory
cytokines IL-6 and IL-8. Cancer Res. 73:3470–3480. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Klymkowsky MW and Savagner P:
Epithelial-mesenchymal transition: A cancer researcher's conceptual
friend and foe. Am J Pathol. 174:1588–1593. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Radisky DC: Epithelial-mesenchymal
transition. J Cell Sci. 118:4325–4326. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee JM, Dedhar S, Kalluri R and Thompson
EW: The epithelial-mesenchymal transition: New insights in
signaling, development, and disease. J Cell Biol. 172:973–981.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cavallaro U and Christofori G: Cell
adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev
Cancer. 4:118–132. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
